Diabetic polyneuropathy (DPN) is a complex and multifactorial entity in which various
factors besides hyperglycemia play an important role. Symptoms of DPN are sensory, motor or autonomic.
Intensive research proved that oxidative stress is the common denominator for the four major
destructive pathways of hyperglycemia including increased hexosamine pathway flux, activation of
Protein kinase-C (PKC) pathway, increased Advanced Glycated End-products (AGEs) formation, and
increased Polyol Pathway flux. National data in Egypt confirms that more than 60% of Egyptian
diabetic patients suffer from neuropathy. The most common complications of DPN are Cardiac
Autonomic Neuropathy (CAN), diabetic foot and ulcers, neuromuscular disability, and anxiety. In
addition, DPN affects the Quality of Life (QoL). According to common clinical practice, the common
diagnostic tools are bed-side diagnosis and electrophysiological tests. Early diagnosis is critical to
improve the prognosis of DPN and therapeutic intervention in the early phase. In this review, we provide
a clear understanding of the pathogenesis, early diagnosis and the good management of DPN.
Since the pathogenesis of DPN is multifactorial, its management is based on combination therapy of
symptomatic; either pharmacological or non-pharmacological treatments, and pathogenic treatment.
Alpha Lipoic Acid (ALA) is a potent anti-oxidant that has several advantages as a pathogenic treatment
of DPN. So, in clinical practice, ALA may be prescribed for patients with early neuropathic deficits and
symptoms. Patient education has an important role in the managemement of DPN.
Objectives:The study aims to assess the real-world incidence of hypoglycemia in patients with Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) in Egypt cohort of the International Operations Hypoglycemia Assessment Tool (IO HAT) study.
Methods:This is a non-interventional study to estimate hypoglycemia in eligible patients with T1DM or T2DM, aged ≥18 years and treated with insulin for >12 months, who have completed self-assessment questionnaires to record demography, treatment information, and hypoglycemia during the 6-month/4-week retrospective and 4-week prospective periods. Data on hypoglycemia for this sub-analysis were collected from DM patients of Egyptian cohort who were recruited in IO HAT study across 36 sites in Egypt between 22 Nov 2014 and 15 Apr 2015.
Results:Percentage of patients who reported at least one hypoglycemic event in the prospective period was any: T1DM: 96.3% (95% confidence interval [CI]. An estimated rate of any and severe hypoglycemia in the prospective period was 63.3 (95% CI: 57.2, 69.9) events per patient year (PPY) and 28.9 (95% CI: 24.8, 33.4) events PPY, respectively, for patients with T1DM and 32.0 (95% CI: 29.8, 34.3) events PPY and 15.5 (95% CI: 14.0, 17.1) events PPY, respectively, for patients with T2DM. Hypoglycemic rate was independent of glycated hemoglobin levels.
Conclusion:The self-reported hypoglycemia data from Egypt confirms that hypoglycemia is under-reported. The high impact of hypoglycemia on the Egyptian DM patients and healthcare system warrants patient education to prevent hypoglycemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.